Do you want to read an article? Please log in or register.
TRAVERSE: Dupilumab reduces severe asthma exacerbation rates and improves lung function regardless of increases in blood eosinophil counts
Asthma
ERS 2024
Related content
ERS 2024
Asthma
BEHAVE: Benralizumab reduces exacerbations and improves asthma control in real-world patients with severe asthma
COPD
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
Respir Med
Vogelmeier CF, Rabe KF, Bhatt SP, Hanania NA, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Maloney J, Dakin P, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM
doi: 10.1016/j.rmed.2025.108015
COPDEmphysema
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM
doi: 10.1016/j.rmed.2024.107846
RECOMMENDED
Further Publications
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
Muro S, Kawayama T, Sugiura H, Seki M, Duncan EA, Bowen K, Marshall J, Megally A, Patel M
doi: 10.1186/s12931-024-02918-8
COMMENTED
COPD
Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
Thorax
Mathioudakis AG, Higham A, Bate S, Chatzimavridou-Grigoriadou V, Sivapalan P, Jensen JS, Felton T, Vestbo J, Singh D
doi: 10.1136/thorax-2024-222547
RECOMMENDED
Asthma
Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Allergy Asthma Immunol Res
Rhee CK, Park JW, Park HW, Noh H, Msihid J, Cho YS
doi: 10.4168/aair.2024.16.4.372
RECOMMENDED
Asthma
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Rimkunas A, Januskevicius A, Vasyle E, Palacionyte J, Kalinauskaite-Zukauske V, Miliauskas S, Malakauskas K
doi: 10.2147/JAA.S509001
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
AsthmaRespiratory Tract Infection
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Respir Med
Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C
doi: 10.1016/j.rmed.2025.108203